Related Experiment Video
Updated: May 31, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Safety and Efficacy of Radiotherapy Plus Immunotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and
Hasnain Wajeeh Saqib1, Mustafa Iqbal Khan2, Tazeem Hayat1
1Riphah International University Islamic International Medical College, Rawalpindi, Pakistan.
Background:
The role of combining radiotherapy (RT) with immune checkpoint inhibitors (ICIs) in advanced hepatocellular carcinoma (HCC) remains unclear. We aimed to evaluate the efficacy and safety of RT plus ICI compared to ICI alone.
Methods:
We systematically searched PubMed, Web of Science, and Cochrane CENTRAL from inception to April 2025. Eligible studies were clinical trials or retrospective cohorts comparing RT + ICI with ICI alone in patients with advanced HCC. Outcomes included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (AEs). Risk of bias was assessed using ROBINS-I. Data were synthesized using a random-effects meta-analysis.
Results:
Eight studies comprising 392 patients were included. RT + ICI was associated with improved outcomes: OS (62.8% vs. 45%), PFS (25.4% vs. 3.6%), ORR (51.1% vs. 27.6%), and DCR (83.1% vs. 60.6%) compared with ICI alone. AEs were more frequent with combination therapy (76.2% vs. 61%). Heterogeneity was moderate to high across several outcomes, and all included studies were retrospective.
Conclusions:
RT combined with ICIs shows promising improvements in survival and tumor response compared to ICI alone in advanced HCC, albeit with increased toxicity. Large randomized trials are needed to confirm efficacy, optimize RT regimens, and identify patients most likely to benefit.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy